IDEC-C2B8 monoclonal antibody data

At the American Society of Clinical Oncology meeting in Philadelphia, IDPH presented positive preliminary results from its completed Phase III trial of IDEC-C2B8 as a single agent in a total of 166 patients with relapsed low-grade or follicular non-Hodgkin's lymphoma. The MAb targets the CD20 antigen, which is expressed on the surface of mature B cells and on B cell tumors.

Patients received four weekly infusions of the compound. Of the first 48 evaluable patients, 23 responded to treatment (47.9 percent), of which 6 were complete responses (12.5 percent) and 17 were partial responses (35.4 percent). A median time to disease progression hasn't been reached, with the median observation time at seven months. ...